# A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension

> **NCT07661329** · PHASE3 · RECRUITING · sponsor: **YS Life Science Co., Ltd.** · enrollment: 600 (estimated)

## Conditions studied

- Primary Open Angle Glaucoma (POAG)
- Ocular Hypertension (OH)

## Interventions

- **DRUG:** Bimatoprost ophthalmic solution 0.01% YSBP
- **DRUG:** bimatoprost ophthalmic solution 0.01% (Lumigan®)

## Key facts

- **NCT ID:** NCT07661329
- **Lead sponsor:** YS Life Science Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-02
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07661329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07661329, "A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07661329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*